Japan
FerroptoCure Inc., founded in 2022 and headquartered in Japan, is a promising player in the oncology sector. The company operates under the slogan "Ferroptosis to Cure", leveraging a novel approach targeting ferroptosis, a cell death mechanism disrupted in cancer cells by oxidative stress resistance.
FerroptoCure’s innovative drugs address this pathway, aiming to overcome cancer cells' resistance to ferroptosis. Successfully targeting this mechanism could yield therapeutic solutions for various cancer types. The company has already advanced its drug candidates to Phase I clinical trials, marking a significant milestone in their development process.
In September 2025, the company secured a $3.00M grant investment from a consortium of investors including ANRI, Japan Science and Technology Agency, Tokyo University of Science Innovation Capital, Diamond Medino Capital, and Vision Incubate. This financial backing underscores investor confidence in FerroptoCure’s potential to innovate in the cancer treatment landscape.
